Search results
15 sie 2024 · The imposed MFP for a 30-day equivalent supply of ELIQUIS, which is the price that Medicare will pay for ELIQUIS as of January 1, 2026, is $231.00.
By 2030, up to 80 drugs will have lower negotiated prices. One of the first ten drugs selected for negotiation is Eliquis, a drug used to treat blood clots, manufactured by Bristol Myers Squibb and Pfizer.
15 sie 2024 · Today, the U.S. Department of Health and Human Services released the “Maximum Fair Price” (MFP) for a 30-day supply of ELIQUIS® (apixaban), which was selected in the first round of government price setting as part of the Inflation Reduction Act (IRA).
15 sie 2024 · Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price. Xarelto, a blood thinner from Johnson & Johnson: $197 negotiated price, down...
15 sie 2024 · HHS Announces Negotiated Prices for Medicare Drugs. HHS has reached agreements with all participating manufacturers on new negotiated, lower drug prices for the first 10 drugs selected for the...
30 sty 2023 · Many of the drugs are inexpensive with the price increases amounting to $1 or less. The drug giant said it is spending $2 billion to upgrade manufacturing to ensure high-quality, reliable...
As previously disclosed, the Company expects Eliquis to face generic entry in the U.S. beginning April 1, 2028. While Eliquis patents continue to be challenged in certain EU countries, patent expiry in key EU markets is expected to occur in the second half of 2026.
